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Background: Intravenous epoprostenol is the only drug proved in a randomized study to reduce mortality in
patients with idiopathic pulmonary arterial hypertension (PAH). However, administration of this drug has procedural
difficulties and a risk of sepsis. Oral drugs provide simple treatment, but their benefit for survival has not been
proven. A recovery of patients with PAH to World Health Organization functional class (WHO-FC) I or II may predict
favorable survival.
Methods: Survival analyses were performed on a historical cohort of 41 patients with PAH. The patients were
43 ± 22 years old, 23 had idiopathic or heritable PAH, and 18 had connective tissue disease-associated PAH. The
baseline was defined as the initial visit to a medical facility.
Results: The median duration of follow-up was 1276 days (108 to 5389 days) and 21 patients died during this
period. The estimated survival times for patients who received intravenous epoprostenol and did and did not
recover to WHO-FC I or II were 4371 ± 577 days and 1172 ± 404 days, respectively. These times for patients who
were not treated with intravenous epoprostenol and did and did not recover to WHO-FC I or II were 4717 ± 554 days
and 925 ± 230 days, respectively. A Cox proportional hazard analysis gave a hazard ratio for death after recovery to
WHO-FC I or II of 0.07 (P < 0.001). In contrast, use of intravenous epoprostenol was not a significant factor affecting
survival (P = 0.96).
Conclusions: Patients with PAH who achieve recovery to WHO-FC I or II without use of intravenous epoprostenol have
similar survival to those who reach the same WHO-FC with use of intravenous epoprostenol. Benign survival of patients
with PAH who have recovered to WHO-FC I or II may extend for several years after onset of the disease.
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Pulmonary arterial hypertension (PAH) carries a signifi-
cant risk of death and patients with PAH who respond
poorly to drug therapy often die within a few years of
onset [1,2]. Among the drugs for PAH, only intravenous
epoprostenol has been proved to prolong survival, at
least in idiopathic PAH, in a randomized trial [3-5]. How-
ever, intravenous epoprostenol has several associated diffi-
culties, including the need for continuous administration
via an infusion pump and a permanent tunneled catheter,
and the possibility of serious adverse events including
pump malfunction, local site infection, catheter obstruc-
tion, and sepsis [4,5]. In contrast, drugs such as endothelin
receptor antagonists (ERAs) or phosphodiesterase type-5
inhibitors (PDE5Is) can be administered orally. However,
despite numerous studies, the effects of ERAs and PDE5Is
on survival have not been established [6-8] and meta-
analyses have not proven a survival benefit for either drug
class [6,7].
Based on this background and given the poor prognosis
of PAH, patients and physicians often encounter a dilemma
in selecting an appropriate treatment regimen. To address
this difficulty, guidelines based on expert consensus on the
diagnosis and treatment of PAH have set treatment goals
that predict a benign course [4,5]. One goal is achievement
of World Health Organization functional class (WHO-FC)
I or II [4]. The WHO-FC is a powerful predictor of survival,
despite large interobserver variation in the assessment
[4,5,9,10], with median survival times of 6 months for
WHO-FC IV, 2.5 years for WHO-FC III, and 6 years for
WHO-FC I and II in untreated patients with idiopathic or
heritable PAH [11]. Several other studies have reached
similar conclusions [12-15].
Few studies have examined differences in survival after
achieving WHO-FC I or II with different drugs. Intra-
venous epoprostenol is widely considered to be the most
potent drug for PAH, whereas ERAs and PDE5Is are
considered less effective [4,5]. However, it is unclear
whether patients who achieve WHO-FC I or II with an
ERA or PDE5I survive for as long as those reaching the
same WHO-FC with epoprostenol. This information is
important for choice of treatment with or without intraven-
ous epoprostenol. Thus, the current study was performed
to examine this issue.
Methods
Patients
We retrospectively reviewed the medical charts of all
patients with idiopathic or connective tissue disease
(CTD)-associated PAH who were referred to our hos-
pital between January 1, 2004 and March 31, 2012. PAH
was defined using the standard definition: mean pulmonary
arterial pressure ≥25 mmHg, pulmonary capillary wedge
pressure ≤15 mmHg, and pulmonary vascular resistance >3Wood Units [4,5]. We excluded patients with a diagnosis of
pulmonary veno-occlusive disease or pulmonary capillary
hemangiomatosis. This resulted in inclusion of 98 patients
with PAH. We subsequently excluded patients with a
congenital shunt because their survival clearly differs
from patients with other types of PAH [16]. We also ex-
cluded patients with co-morbidities that could affect
survival, such as those with malignancy. The 41 patients
who were finally included in the study (Figure 1) were
selected by a committee blinded to patient identification
and clinical course after the beginning of management.
The characteristics of the patients at the time of their
initial visit to a medical facility were collected from
medical records. The institutional ethics committee of
our hospital approved the study protocol. The ethics
guidelines of our institute, which is approved by the
Ethics Committee of Nagoya City University Graduate
School of Medical Sciences, do not require written in-
formed consent from each patient on the condition that
personally identifiable information is excluded from the
study results.
Survival analysis
We performed two survival analyses using different
definitions of the baseline. In the first analysis, this was
defined as the day of the first visit to a medical facility
for a symptom of PAH. In the second analysis, the
baseline was defined as the day of initiation of epoproste-
nol in patients administered this drug, and as the day of
final escalation of medication in patients who did not re-
ceive intravenous epoprostenol. All patients were asked to
visit our outpatient clinic every four weeks for adjustment
of therapy and to allow collection of clinical information.
In addition to these periodical contacts, the investigators
and patients sometimes communicated by telephone. The
patients were divided into 4 groups based on recovery or
no recovery to WHO-FC I or II after 12-week treatment
and treatment with or without intravenous epoprostenol:
those who received intravenous epoprostenol and subse-
quently recovered to WHO-FC I or II (Group 1); those
who received intravenous epoprostenol, but failed to
recover to WHO-FC I or II (Group 2); those who did
not receive intravenous epoprostenol, but recovered to
WHO-FC I or II after treatment with another drug
(Group 3); and those who did not receive intravenous
epoprostenol and failed to recover to WHO-FC I or II
(Group 4).
Statistical analysis
Statistical analyses were performed with the Statistical
Package for Social Science version 15.0 for Windows
(SPSS Inc., Chicago, IL). Survival times were defined as
the length of time a patient lived from the baseline date
to Dec 31, 2012. Continuous variables except estimated
Clinically diagnosed as 
PAH, 98
Eisenmenger syndrome, 24




Died within 3 months, 7
Enrollment, 41
Missing data, 16
Figure 1 STARD flow chart of the disposition of patients in the study.
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http://www.biomedcentral.com/1756-0500/7/359survival time are expressed as the mean ± the standard
deviation. For comparison among groups, chi-square test
was used for categorical variables and one-way ANOVA
followed by Bonferroni's post-hoc comparisons tests for
continuous variables. The prognostic values of the vari-
ables were tested using Cox proportional-hazards regres-
sion analyses. The results are expressed as hazard ratios
with 95% confidence intervals. A Kaplan-Meier estimate
was used to calculate the average survival time and sur-
vival rate. Estimated survival times are expressed as the
mean ± standard error (range of 95% confidence interval




The characteristics of the patients at their initial visit to a
medical facility are shown in Table 1. Most were in
WHO-FC III (71%) and almost 25% were in WHO-FC IV.
The numbers of patients with idiopathic or heritable PAH
and CTD-associated PAH were similar. Hemodynamic
data at first right heart catheterization are also shown in
Table 1. These data reflect the advanced WHO-FC:
the hemodynamic variables were fairly severe and the
6-minute-walk distances were relatively short. The 2
patients in WHO-FC II at the first visit to a medical
facility both advanced to WHO-FC III and received
further treatment: one with and one without intraven-
ous epoprostenol. The duration of follow-up from the
initial visit to a medical facility ranged from 108 to
5389 days and the 3rd quartiles was 2769 days. Death
occurred in 21 patients. Treatment at the end of follow-up
(death or the end of the study) is shown in Table 2. More
than half of the patients received epoprostenol with or
without an ERA or a PDE5I. In Japan, epoprostenol,
bosentan, ambrisentan, sildenafil, tadalafil, and beraprost
are approved for treatment of PAH.The numbers of patients of Groups 1 to 4 (defined in
the Methods) were 13, 9, 9, and 10, respectively. Compari-
sons among 4 groups found some statistically significant
differences between Group 1 and 4 or Group 3 and 4 in
age, WHO-FC, right atrial pressure, and 6-munte-walk
distance (Table 1). ERA use was rarer in patients on epo-
prostenol than in those not (Table 2).
Effects of recovery to WHO-FC I or II on survival period
from the initial visit to a medical facility
Kaplan-Meier estimates of survival from the first visit to
a medical facility are shown in Figure 2. The survival
curves for the 4 groups roughly divided into two types,
with patients who recovered to WHO-FC I or II generally
having longer survival than patients who did not achieve
this recovery. Survival times in groups 1 to 4 were 4371 ±
577 days (3240 to 5503 days), 1172 ± 404 days (380 to
1695 days), 4717 ± 554 days (3630 to 5805 days), and
925 ± 230 days (474 to 1375 days), respectively. Cox
proportional hazard analysis gave a hazard ratio for
death of recovery to WHO-FC I or II of 0.07 (95% CI
0.02 to 0.26, P < 0.001). Intravenous epoprostenol had
no significant influence on survival (P = 0.96).
Effects of recovery to WHO-FC I or II on survival period
based on medication initiation
Kaplan-Meier estimates of survival from the start of
intravenous epoprostenol or the last escalation of oral
medication are shown in Figure 3. This analysis also re-
sulted in each of the 4 groups falling into one of two
types, with patients who recovered to WHO-FC I or II
having longer survival than those who failed to show this
recovery. Survival times in groups 1 to 4 were 2583 ±
311 days (1973 to 3192 days), 930 ± 390 days (165 to
1694 days), 2242 ± 445 days (1368 to 3114 days), and
314 ± 135 days (49 to 579 days), respectively. Cox pro-
portional hazard analysis gave a hazard ratio for death of
Table 1 Patient characteristics at the time of initial visit to a medical facility
Variables All Group 1 Group 2 Group 3 Group 4
Age (years) * 43 ± 22 38 ± 18‡ 48 ± 22 52 ± 21 66 ± 9‡
Women/Men† 34 (83) / 7 (17) 10 (24) / 0 (0) 6 (15) / 3 (7) 9 (22) / 0 (0) 9 (22) / 1 (2)
WHO-FC†§ II/III/IV 2(5) / 29(71) / 10(24) 0 (0) / 12 (29) / 1 (2) 0 (0) / 5 (12) / 4 (10) 2 (5) / 7 (17) / 0 (0) 0 (0) / 5 (12) / 5 (12)
Etiology† Idiopathic 22(54) 9 (22) 6 (15) 2 (5) 5 (12)
Heritable 1(2) 0 (0) 0 (0) 1 (2) 0 (0)
CTD SSc 12(29) 1 (2) 3 (7) 4 (10) 4 (10)
MCTD 3(7) 2 (5) 0 (0) 1 (2) 0 (0)
SLE 2(5) 1 (2) 0 (0) 1 (2) 0 (0)
PM 1(2) 0 (0) 0 (0) 0 (0) 1 (2)
Hemodynamics* mPAP (mmHg) 51 ± 16 57 ± 21 53 ± 5 43 ± 13 45 ± 11
RAP (mmHg) 8 ± 6 6 ± 4|| 8 ± 4 6 ± 4# 14 ± 8||,#
CI (L/min/m2) 2.1 ± 0.6 2.1 ± 0.6 2.3 ± 0.5 1.9 ± 0.5 2.1 ± 0.6
PVR (dyne/sec/cm−5) 1058 ± 492 1368 ± 439 981 ± 314 884 ± 526 1039 ± 605
SvO2 (%) 60 ± 10 61 ± 9 50 ± 17 63 ± 9 60 ± 10
6MWD (m)* 196 ± 188 267 ± 164 150 ± 230 401 ± 39** 56 ± 106**
*Average ± standard deviation, †Number (%) of patients, ‡p = 0.004 between Group 1 and 4, §p = 0.010, **p = 0.03 between Group 3 and 4, ||p = 0.02 between
Group 1 and 4, #p = 0.02 between Group 3 and 4 in RAP. CI: cardiac index, CTD: connective tissue disease, MCTD: mixed connective tissue disease, mPAP: mean
pulmonary arterial pressure, PM: polymyositis, PVR: pulmonary vascular resistance, RAP: right atrial pressure, SLE: systemic lupus erythematosus, SSc: scleroderma,
SvO2: oxygen saturation of mixed venous blood, WHO-FC: World Health Organization functional class, 6MWD: 6-minute-walk distance.
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0.44, P = 0.001). Again, intravenous epoprostenol had no
significant influence on survival (P = 0.33).
Recovery to WHO-FC I or II and survival in idiopathic and
CTD-associated PAH
The numbers of cases of idiopathic or heritable PAH and
CTD-associated PAH in groups 1 to 4 were shown in
Table 1. The relationship between disease type and clinical
course (groups 1 to 4) was not significant (P = 0.339). Cox
proportional hazard analysis gave P = 0.174 for disease
type and P = 0.001 for clinical course.
Discussion
This study shows that recovery to WHO-FC I or II in
patients with PAH increases the survival period, regardless
of treatment with intravenous epoprostenol or an oralTable 2 Treatment at the end of follow-up (death or the
end of the study)
Treatment Number (%) of patients
All Group 1 Group 2 Group 3 Group 4
Epoprostenol* 22 (54) 13 (32) 9 (22) 0 (0) 0 (0)
ERA† 9 (22) 1 (2) 0 (0) 4 (10) 4 (10)
PDE5I 14 (34) 3 (7) 1 (2) 4 (10) 6 (15)
Beraprost 3 (7) 0 (0) 0 (0) 1 (2) 2 (4)
Variables are number (%) of patients. ERA: endothelin receptor antagonist,
PDE5I: phosphodiesterase 5 inhibitor. Some patients received more than one
of the drugs. *p < 0.001, †p = 0.035.ERA or PDE5I. Among the patients, 25% were followed
for more than 2750 days (7.5 years); thus, this is a follow-
up study with a long observation period. Benign survival
of patients who recovered to WHO-FC I or II seems to be
preserved for at least 4000 days after their first visit to a
medical facility. These results imply that meeting the
treatment target is vital, but the specific drug therapy is
less important in developing a treatment plan for a patient
with PAH. This finding may assist patients and physicians
in the choice of drug for PAH.
Guidelines recommend that the patient's status should
remain in the range of the treatment goal, while few
guidelines provide a comparison among drugs [4,5,17].
The European guidelines described the following drugs as
recommendations for initial treatment in nonvasoreactive
patients in WHO-FC III: ambrisentan, bosentan, sitaxen-
tan (now withdrawn), sildenafil, intravenous epoprostenol,
inhaled iloprost, tadarafil, and subcutaneous or inhaled
treprostinil [4]. The expert consensus document from the
United States recommends the following drugs for patients
at lower risk, which fits with WHO-FC II or III: ERAs,
PDE5Is, intravenous epoprostenol, intravenous or subcuta-
neous treprostinil, and inhaled iloprost [5]. Neither of these
guidelines provide a reference for choice of one drug [4,5],
probably because head-to-head comparisons of drugs are
not available [4]. Thus, a particular drug cannot be selected
in an evidence-based manner. The results of the current
study provide confidence to patients and physicians that
the selected drug is not very important if recovery to
WHO-FC class I or II is obtained.
Figure 2 Kaplan–Meier survival curves for patients from the day of their first visit to a medical facility. The patients were divided into 4
groups: Group 1: intravenous epoprostenol and recovery to WHO-FC I or II; Group 2: intravenous epoprostenol, but failure to recover to WHO-FC I
or II; Group 3: no intravenous epoprostenol, but recovery to WHO-FC I or II; and Group 4: no intravenous epoprostenol and failure to recover to
WHO-FC I or II. Cox proportional hazard analysis gave a hazard ratio for death compared to recovery to WHO-FC II or better of 0.07 (95%
confidence interval: 0.02 to 0.26, P < 0.001). Use of intravenous epoprostenol had no significant influence on survival (p = 0.96).
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WHO-FC as a marker of the degree of recovery, but not
other medical parameters. The WHO-FC system was
modified from the New York Heart Association func-
tional class (NYHA-FC) [18] and both the WHO-FCFigure 3 Kaplan-Meier estimates of survival time from the start of intra
patients were divided into 4 groups: Group 1: intravenous epoprostenol and
to recover to WHO-FC I or II; Group 3: no intravenous epoprostenol, but recov
failure to recover to WHO-FC I or II. Cox proportional hazard analysis gave a h
(95% confidence interval: 0.05 to 0.44, P < 0.001). Use of intravenous epoprostand NYHA-FC depend on the physician’s interpretation
of ordinary physical activity, slight limitation, or marked
limitation [18]. This may cause high interobserver vari-
ability [10,19]. Despite this problem, the WHO-FC is a
powerful predictor of survival and the severity of PAH isvenous epoprostenol or the last increase of oral medication. The
recovery to WHO-FC I or II; Group 2: intravenous epoprostenol, but failure
ery to WHO-FC I or II; and Group 4: no intravenous epoprostenol and
azard ratio for death compared to recovery to WHO-FC II or better of 0.15
enol had no significant influence on survival (p = 0.33).
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The WHO-FC has proved to be clinically useful and is used
routinely in most randomized clinical trials. Improvement
of WHO-FC after medical treatment predicts the long-
term survival of patients with PAH [12,15], with patients in
WHO-FC I or II at baseline and follow-up after drug ther-
apy having a survival probability of 90% after 5 years, while
those in WHO-FC III or IV before and after drug therapy
have a survival probability of 34% after 5 years [15]. Patients
with PAH who improve from WHO-FC III to I or II after
drug therapy also have better survival than those who
remain in WHO-FC III [12,15]. Thus, despite the large
interobserver variability, the WHO-FC is valuable for
assessment of the status of patients with PAH. This in-
dicates that the validity of the results in the current
study is decreased little by the lack of other clinical
parameters.
Group 4, a group of patients who did not receive intra-
venous epoprostenol and failed to recover to WHO-FC I
or II, showed some particular characteristics (Table 1). In-
tergroup comparison found that their ages were older and
their right atrial pressure and 6-minute-walk distance were
worse than those of patients who recovered to WHO-FC I
or II (Group 1 or 3). This suggests that some of them gave
up intravenous epoprostenol because of their advanced age
and inability of self-supervision of home therapy, and that
some of them did so due to too advanced disease.
This study has several other limitations. First, it was a
retrospective study. Second, as a single-center study, some
referral bias may be present. Third, the limited sample size
may impair the statistical power of the analyses. Fourth,
comparisons between ERAs and PDE5Is and between
idiopathic or heritable PAH and CTD-associated PAH
were not performed because of the limited sample size.
Fifth, this study did not consider changes in treatment
after the first 12 weeks following initiation of epoprostenol
(in patients administered this drug) or final escalation of
medication (in patients who did not receive intravenous
epoprostenol). Within these limitations, the results of the
study suggest that patients who recover to WHO-FC I
or II have a better prognosis than those without this
recovery, regardless of the disease type and drug treat-
ment. Validation of this finding will require a trial in a
larger population.
Conclusion
Patients with PAH who achieve recovery to WHO-FC I or
II with ERAs or PDE5Is survive for as long as those who
reach the same WHO-FC with intravenous epoprostenol.
Benign survival of patients who recover to WHO-FC I or
II may extend for several years after onset of the disease.
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